At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
4 articles- Samsung Bioepis宣布其Keytruda (Pembrolizumab)候选生物类似药SB27的积极1期和3期初步研究数据Business Wire Pharma·2026-06-29press release
- <a href="https://www.fiercepharma.com/pharma/asco-preview-expectations-jacked-akeso-ivonescimab-face-scrutiny-high-stakes-plenary" hreflang="en">ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary</a>FiercePharma
- <a href="https://www.fiercebiotech.com/pharma/asco-akeso-ivonescimab-bests-pd-1-inhibitor-squamous-nsclc-overall-survival" hreflang="en">ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%</a>FierceBiotech
- <a href="https://www.fiercepharma.com/pharma/asco-akeso-ivonescimab-bests-pd-1-inhibitor-squamous-nsclc-overall-survival" hreflang="en">ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%</a>FiercePharma
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
Evaluation of JSKN016 Combination Therapy in Subjects With Advanced Non-Small Cell Lung Cancer: A Phase Ib Study
In Brief
A Phase 1 clinical trial evaluating JSKN016, Carboplatin, and 5 other interventions for Advanced Non-small Cell Lung Cancer. Currently recruiting, targeting 288 participants across 1 site.
Detailed Summary
This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
Study Details
Timeline
Interventions
Administered intravenously according to protocol.
AUC 5, Q3W, administered intravenously according to protocol.
160mg（cohort1A-b）or 80mg（cohort 5）, qd, administered according to protocol.
20mg/kg, Q3W, administered intravenously according to protocol.
60mg/m\^2, Q3W, administered intravenously according to protocol.
200mg, Q3W, administered intravenously according to protocol.
200mg, Q3W, administered intravenously according to protocol.